In vivo and in vitro sperm production: an overview of the challenges and advances in male fertility restoration.

IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Clinical and Experimental Reproductive Medicine-CERM Pub Date : 2024-09-01 Epub Date: 2024-03-25 DOI:10.5653/cerm.2023.06569
Zahra Bashiri, Seyed Jamal Hosseini, Maryam Salem, Morteza Koruji
{"title":"In vivo and in vitro sperm production: an overview of the challenges and advances in male fertility restoration.","authors":"Zahra Bashiri, Seyed Jamal Hosseini, Maryam Salem, Morteza Koruji","doi":"10.5653/cerm.2023.06569","DOIUrl":null,"url":null,"abstract":"<p><p>Male infertility can be caused by genetic anomalies, endocrine disorders, inflammation, and exposure to toxic chemicals or gonadotoxic treatments. Therefore, several recent studies have concentrated on the preservation and restoration of fertility to enhance the quality of life for affected individuals. It is currently recommended to biobank the tissue extracted from testicular biopsies to provide a later source of spermatogonial stem cells (SSCs). Another successful approach has been the in vitro production of haploid male germ cells. The capacity of SSCs to transform into sperm, as in testicular tissue transplantation, SSC therapy, and in vitro or ex vivo spermatogenesis, makes them ideal candidates for in vivo fertility restoration. The transplantation of SSCs or testicular tissue to regenerate spermatogenesis and create embryos has been achieved in nonhuman mammal species. Although the outcomes of human trials have yet to be released, this method may soon be approved for clinical use in humans. Furthermore, regenerative medicine techniques that develop tissue or cells on organic or synthetic scaffolds enriched with bioactive molecules have also gained traction. All of these methods are now in different stages of experimentation and clinical trials. However, thanks to rigorous studies on the safety and effectiveness of SSC-based reproductive treatments, some of these techniques may be clinically available in upcoming decades.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Reproductive Medicine-CERM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5653/cerm.2023.06569","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Male infertility can be caused by genetic anomalies, endocrine disorders, inflammation, and exposure to toxic chemicals or gonadotoxic treatments. Therefore, several recent studies have concentrated on the preservation and restoration of fertility to enhance the quality of life for affected individuals. It is currently recommended to biobank the tissue extracted from testicular biopsies to provide a later source of spermatogonial stem cells (SSCs). Another successful approach has been the in vitro production of haploid male germ cells. The capacity of SSCs to transform into sperm, as in testicular tissue transplantation, SSC therapy, and in vitro or ex vivo spermatogenesis, makes them ideal candidates for in vivo fertility restoration. The transplantation of SSCs or testicular tissue to regenerate spermatogenesis and create embryos has been achieved in nonhuman mammal species. Although the outcomes of human trials have yet to be released, this method may soon be approved for clinical use in humans. Furthermore, regenerative medicine techniques that develop tissue or cells on organic or synthetic scaffolds enriched with bioactive molecules have also gained traction. All of these methods are now in different stages of experimentation and clinical trials. However, thanks to rigorous studies on the safety and effectiveness of SSC-based reproductive treatments, some of these techniques may be clinically available in upcoming decades.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体内和体外精子生成:男性生育能力恢复的挑战和进展概览。
男性不育症可由遗传异常、内分泌失调、炎症、接触有毒化学物质或接受性腺毒性治疗引起。因此,最近的一些研究集中于保留和恢复生育能力,以提高患者的生活质量。目前建议将从睾丸活检中提取的组织建立生物库,以便日后提供精原干细胞(SSCs)来源。另一种成功的方法是体外培养单倍体男性生殖细胞。在睾丸组织移植、造血干细胞治疗、体外或体内精子发生过程中,造血干细胞具有转化为精子的能力,这使它们成为体内生育力恢复的理想候选者。移植造血干细胞或睾丸组织以再生精子和制造胚胎的方法已在非人类哺乳动物物种中实现。虽然人类试验的结果尚未公布,但这种方法可能很快就会被批准用于人类临床。此外,在富含生物活性分子的有机或合成支架上培育组织或细胞的再生医学技术也受到了广泛关注。所有这些方法目前都处于不同的实验和临床试验阶段。不过,由于对基于造血干细胞的生殖治疗的安全性和有效性进行了严格研究,其中一些技术可能会在未来几十年内应用于临床。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
0
期刊最新文献
In vivo and in vitro sperm production: an overview of the challenges and advances in male fertility restoration. Outcomes of female reproductive performance with assisted reproductive techniques after recent mild to moderate COVID-19 infections: An observational study. p,p'-DDT induces apoptosis in human endometrial stromal cells via the PI3K/AKT pathway and oxidative stress. Metabolomic profiling of embryo culture media in patients with repeated implantation failure during assisted reproductive technology cycles. Systematic Review of the roles of Inositol and Vitamin D in improving fertility among patients with Polycystic Ovary Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1